Engineers Gate Manager’s Bicycle Therapeutics BCYC Stock Holding History

Engineers Gate Manager’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$164K	Buy	35,400 +11,353	+47%	+$64.9K	﹤0.01%	1954
2025 Q4	$170K	Buy	24,047 +10,626	+79%	+$78.3K	﹤0.01%	1836
2025 Q3	$104K	Sell	13,421 -1,981	-13%	-$15K	﹤0.01%	2003
2025 Q2	$107K	Buy	+15,402	New	+$123K	﹤0.01%	1986
2023 Q4	–	Sell	-16,076	Closed	-$323K	–	1970
2023 Q3	$323K	Buy	+16,076	New	+$368K	0.01%	1283
2022 Q2	–	Sell	-7,770	Closed	-$341K	–	1910
2022 Q1	$341K	Buy	+7,770	New	+$363K	0.01%	1310

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Engineers Gate Manager's BCYC Position: Q1 2026 in Review

Engineers Gate Manager increased its Bicycle Therapeutics (BCYC) stake by 47% in Q1 2026, buying an estimated $64.9K and bringing the position to 35,400 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Engineers Gate Manager first reported a position in BCYC in Q1 2022 and has held it in 6 quarters since. The position peaked at $341K in Q1 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Engineers Gate Manager held 35,400 shares of Bicycle Therapeutics worth $164K as of Q1 2026.
Engineers Gate Manager bought 11,353 Bicycle Therapeutics shares in Q1 2026, an estimated $64.9K.
Bicycle Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1954 holding.
Engineers Gate Manager first reported a position in Bicycle Therapeutics in Q1 2022 and has held it in 6 quarters since.
Engineers Gate Manager's Bicycle Therapeutics position peaked at $341K in Q1 2022.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.